A. Musafer

Combination Osimertinib and Gefitinib in C797S and T790M EGFR‐Mutated Non–Small Cell Lung Cancer

H. Do, A. Dobrovic, T. John, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Synthetic DNA Construct to Evaluate the Recovery Efficiency of Cell-Free DNA Extraction and Bisulfite Modification.

H. Do, A. Musafer, V. Muralidharan, 2021, Clinical chemistry.

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

N. Traficante, A. deFazio, D. Bowtell, 2021, Cancer Research.

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

N. Traficante, A. deFazio, D. Bowtell, 2020, bioRxiv.

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

A. Tinker, A. Oza, D. Provencher, 2021, Nature Communications.

Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease.

H. Do, A. Dobrovic, T. John, 2019, Journal of thoracic disease.

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

R. Scolyer, A. Dobrovic, G. Long, 2021, Frontiers in Immunology.

Comparison of 3 Methodologies for Genotyping of Small Deletion and Insertion Polymorphisms.

H. Do, C. Christophi, A. Musafer, 2016, Clinical chemistry.